AAV Suspension Platform Generations:
Continuous Improvement Leading to
Increased Viral Vector Titer and Yield

Just fill out the form below to register.

Presenters:

Yiyu Dong is the Head of Cell Line Development group in the Process and Technology Development department at WuXi Advanced Therapies. He has more than fifteen years of experience in cell line development and process development.  Yiyu has published twenty six scientific articles in peer-reviewed journals. He holds a Ph.D. degree from Peking University in China.  

.

 

David Barnard

Senior Scientist, Process and Technology Development
WuXi Advanced Therapies

 

David Barnard is a Senior Scientist in the Process and Technology Development (PTD) department at WuXi Advanced Therapies. His focus in PTD is the scale-up and tech transfer of platform processes to GMP manufacturing. He holds a PhD in chemistry from Temple University.